Opinion

Video

The Role of CAR T-Cell Therapy in R/R DLBCL

Author(s):

Sonali Smith, MD,Krish Patel, MD

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
CBF-AML | Image credit: © Motion Pics - stock.adobe.com
June 14th 2025

Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
March 26th 2025

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

Asciminib in Newly Diagnosed CML in Chronic Phase | Image Credit: © LELISAT - stock.adobe.com
June 13th 2025

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Image credit: © Maris – stock.adobe.com
June 13th 2025

Ponatinib Is Associated With Improved Survival in Ph+ ALL With MRD Positivity After Induction

Iptacopan in paroxysmal nocturnal hemoglobinuria: © Bipul Kumar - stock.adobe.com
June 13th 2025

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria